Kobayashi Roger H, Maltese Joanna, Litzman Jiří, Kreuwel Huub, Zekoll Theresa, Kobayashi Ai Lan, Gupta Sudhir
Division of Pediatric Immunology and Allergy, School of Medicine, University of California, Los Angeles, CA, USA.
Medical Affairs, Octapharma USA, Inc, Paramus, NJ, USA.
Immunotherapy. 2024;16(20-22):1235-1245. doi: 10.1080/1750743X.2024.2436343. Epub 2024 Dec 8.
This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment. For these reasons, it's important to develop flexible infusion regimens tailored to meet individual patient needs. Patient-centric strategies that promote shared decision-making and awareness of patient status not only promote medical efficacy but also enhance the overall patient experience. The authors of this report call attention for a need to shift toward more adaptable and individualized SCIG treatment plans for PAD patients whose needs may change over the long-term course of treatment.
本报告深入探讨了与原发性抗体缺陷病（PAD）患者灵活、定制化皮下免疫球蛋白（SCIG）输注方案相关的挑战及潜在解决方案。免疫缺陷病，尤其是PAD治疗方面的进展，已将致命疾病转变为慢性、复杂的长期病症，这使得坚持治疗成为一个关键问题。传统的SCIG输注方案虽在临床上有效，但可能并不总是与患者多样的生活方式、不断变化的生活模式和责任相契合，这可能导致漏服剂量，依从性降低，从而带来潜在健康风险并损害治疗的整体效果。出于这些原因，制定适合个体患者需求的灵活输注方案很重要。以患者为中心的策略，促进共同决策和对患者状况的了解，不仅能提高医疗效果，还能提升患者的整体体验。本报告的作者呼吁，对于那些在长期治疗过程中需求可能发生变化的PAD患者，需要转向更具适应性和个性化的SCIG治疗方案。
